Search clinical trials for: CHR-5154

Total 2503 results

GlaxoSmithKline

Terminated

Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers

Arthritis, Rheumatoid

United Kingdom
Canopy Growth Corporation
University of Arkansas

Completed

A Randomized Controlled Test of the Effects of CHI-554 on Fear.

Anxiety | Fear | Panic

United States
Seca GmbH & Co. Kg.

Completed

Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)

Kidney Diseases

Germany
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
NYU Langone Health
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

Patient-Centered Cancer Prevention In Chinese Americans

H. Pylori Infection

United States
Arcutis Biotherapeutics, Inc.

Completed

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (ARRECTOR)

Scalp Psoriasis

United States, Canada
PATH
GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaborators

Completed

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Influenza | Vaccine

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Subcutaneous Fat

Australia
AbbVie

Completed

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

ABBV-154

United States
Trethera

Recruiting

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Oncology | Solid Tumor, Adult

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Abbott Medical Devices

Completed

AVJ-514 Japan Trial

Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With Insufficiency

Japan
Heidelberg Pharma AG

Terminated

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

Advanced Solid Tumours

United Kingdom
Inovio Pharmaceuticals

Completed

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Prostate Cancer

United States
Johnson & Johnson Consumer and Personal Products...

Completed

A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions

Coitus

United States
Shanghai Zhimeng Biopharma, Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants

Healthy Volunteers

United States
Shanghai Zhimeng Biopharma, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia

Healthy Volunteers

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Dercum's Disease

United States
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Cellulite

United States
AbbVie

Terminated

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (AIM-CD)

Crohn's Disease

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, Spain, Taiwan, United...
MedImmune LLC

Completed

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

Advanced Malignancies

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
Arcutis Biotherapeutics, Inc.

Completed

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Seborrheic Dermatitis

United States
Heidelberg Pharma AG

Terminated

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Advanced Solid Tumours

United Kingdom
Blueprint Medicines Corporation

Completed

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

China, Korea, Republic of, Taiwan, Hong Kong, United Kingdom, United States, France, Spain, Switzerland, Singapore, Germany, Italy
Chimeric Therapeutics

Not yet recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

Myocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease
Confo Therapeutics

Completed

Safety and Tolerability of CFTX-1554 in Healthy Subjects

Healthy

Netherlands
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Seborrheic Dermatitis

United States, Canada
Caliway Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Dercum's Disease
Johnson & Johnson Consumer and Personal Products...

Completed

A Four-Week Study to Measure the Effectiveness of an Experimental Mouthwash Used After Teeth Cleaning

Dental Plaque

United States
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Seborrheic Dermatitis

United States, Canada
Chroma Therapeutics

Completed

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies (CHR-2845-001)

Lymphoid Malignancies | Hematological Disease

France, Belgium, Netherlands
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Plaque Psoriasis

United States, Australia, Bulgaria, Canada
Boehringer Ingelheim

Completed

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

Healthy
University of California, Irvine
University of Maryland, Baltimore County

Not yet recruiting

Youth Nominated Support Team (YST)

Suicide | Psychosis | Health Care Utilization | Family Members
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Australia, Canada, Czechia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukraine
Arcturus Therapeutics, Inc.

Recruiting

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

COVID-19 | Corona Virus Infection | SARS-CoV-2 Infection

United States, Singapore
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Subcutaneous Fat

United States, Australia
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
University Hospital, Basel, Switzerland

Completed

Smart SCALEs With Bioimpedance Analysis for Treatment Guidance in Decompensated Heart Failure (SCALE HF)

Heart Failure; With Decompensation

Switzerland
Population Council
Centers for Disease Control and Prevention; Ministry of Health, Thailand; National... and other collaborators

Completed

A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women

HIV Infections

Thailand
ImmPACT Bio

Recruiting

A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Nephritis

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Population Council
National Institute of Allergy and Infectious Diseases (NIAID); United States... and other collaborators

Completed

Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission

HIV Infections | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Neisseria Gonorrhoeae

South Africa
Population Council
United States Agency for International Development (USAID); Bill and Melinda...

Completed

Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission

HIV Infections | Sexually Transmitted Diseases | AIDS | HIV Seroconversion

South Africa

Search clinical trials for: CHR-5154

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations